PCLAF

Across TCGA pan-cancer cohorts, PCLAF RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of PCLAF’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PCLAF RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PCLAF is over-expressed in tumor.

HNSC, KIRC, and BLCA are the cancer types where PCLAF tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCLAF RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.961	<.001	12	view →
KIRC	Male	All	+1.587	<.001	12	view →
BLCA	All	IV	+3.072	<.001	11	view →
KIRP	Male	III,IV	+2.279	<.001	11	view →
THCA	All	III,IV	+0.976	<.001	10	view →
LUSC	Female	II,III,IV	+3.508	<.001	9	view →
LUAD	Male	III,IV	+3.035	<.001	9	view →
LIHC	Male	All	+1.792	<.001	9	view →
UCEC	All	III,IV	+4.122	<.001	8	view →
STAD	Female	All	+2.735	<.001	8	view →
COAD	Female	II,III,IV	+1.252	<.001	8	view →
BRCA	All	III,IV	+2.739	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

PCLAF–HNSC

Open the HNSC breakdown →